S.Biomedics Co., Ltd. (KOSDAQ: 304360)
South Korea
· Delayed Price · Currency is KRW
18,860
-950 (-4.80%)
Nov 18, 2024, 1:21 PM KST
S.Biomedics Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2017 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2017 |
Net Income | -9,771 | -7,524 | -6,327 | -5,667 | -7,747 | -8,098 | Upgrade
|
Depreciation & Amortization | 1,685 | 1,553 | 1,517 | 1,448 | 1,349 | 1,267 | Upgrade
|
Loss (Gain) From Sale of Assets | -22.14 | -5.49 | - | - | - | -0.07 | Upgrade
|
Loss (Gain) From Sale of Investments | -44.88 | -51.81 | -6.77 | -0.24 | -89.31 | -208.6 | Upgrade
|
Stock-Based Compensation | 70.25 | 86.21 | 148.08 | 217.39 | 326.65 | 500.34 | Upgrade
|
Provision & Write-off of Bad Debts | 85.31 | 174.99 | -160.05 | -188.31 | 447.77 | 124.63 | Upgrade
|
Other Operating Activities | 3,690 | 1,767 | 3,105 | 1,666 | -214.12 | -510.31 | Upgrade
|
Change in Accounts Receivable | 171.48 | -771.8 | -697.48 | 440.6 | -417.1 | 135.15 | Upgrade
|
Change in Inventory | -1,213 | -830.05 | -817.71 | -204.21 | -45.37 | 258.75 | Upgrade
|
Change in Accounts Payable | -262.11 | 63.31 | 379.86 | -423.02 | -63.87 | 27.16 | Upgrade
|
Change in Unearned Revenue | - | - | - | - | - | 41.3 | Upgrade
|
Change in Other Net Operating Assets | -257.8 | -610.82 | -347.05 | -576.36 | 1,016 | -452.55 | Upgrade
|
Operating Cash Flow | -5,868 | -6,149 | -3,205 | -3,287 | -5,437 | -6,915 | Upgrade
|
Capital Expenditures | -1,435 | -1,847 | -9,295 | -474.49 | -182.63 | -553.42 | Upgrade
|
Sale of Property, Plant & Equipment | 22.14 | 22.14 | - | - | - | - | Upgrade
|
Sale (Purchase) of Intangibles | - | - | -149.39 | -15.8 | -6.81 | - | Upgrade
|
Investment in Securities | 6,886 | -6,155 | 2,708 | -3,445 | 8,996 | 2,485 | Upgrade
|
Other Investing Activities | -479.47 | -843.25 | -43.69 | -64.87 | -8.56 | -40.19 | Upgrade
|
Investing Cash Flow | 4,994 | -8,824 | -6,871 | -3,990 | 8,788 | 1,891 | Upgrade
|
Long-Term Debt Issued | - | - | 7,000 | 4,860 | 1,400 | 1,010 | Upgrade
|
Total Debt Issued | - | - | 7,000 | 4,860 | 1,400 | 1,010 | Upgrade
|
Short-Term Debt Repaid | - | - | - | - | -138.5 | -24.3 | Upgrade
|
Long-Term Debt Repaid | - | -1,156 | -732.69 | -1,061 | -446.73 | -421.8 | Upgrade
|
Total Debt Repaid | -1,267 | -1,156 | -732.69 | -1,061 | -585.23 | -446.1 | Upgrade
|
Net Debt Issued (Repaid) | -1,267 | -1,156 | 6,267 | 3,799 | 814.93 | 563.9 | Upgrade
|
Issuance of Common Stock | 751.38 | 14,282 | - | - | 52.5 | 5,376 | Upgrade
|
Other Financing Activities | 29.74 | -808.56 | 852.9 | 362.18 | 144.46 | -151.87 | Upgrade
|
Financing Cash Flow | -486 | 12,318 | 8,020 | 4,161 | 2,432 | 5,788 | Upgrade
|
Foreign Exchange Rate Adjustments | 2.18 | -0.86 | -9.47 | 59.35 | -20.4 | -5.87 | Upgrade
|
Miscellaneous Cash Flow Adjustments | -0 | -0 | - | - | - | - | Upgrade
|
Net Cash Flow | -1,358 | -2,656 | -2,066 | -3,057 | 5,763 | 758.25 | Upgrade
|
Free Cash Flow | -7,303 | -7,996 | -12,501 | -3,762 | -5,620 | -7,468 | Upgrade
|
Free Cash Flow Margin | -61.36% | -61.00% | -103.20% | -42.42% | -105.65% | -148.95% | Upgrade
|
Free Cash Flow Per Share | -642.81 | -731.44 | -1223.19 | -370.56 | -555.91 | -767.82 | Upgrade
|
Cash Interest Paid | 493.56 | 487.05 | 156.16 | 158.4 | 184.78 | 160.96 | Upgrade
|
Cash Income Tax Paid | 74.41 | 31.47 | 3.22 | -20.09 | -16.97 | 22.8 | Upgrade
|
Levered Free Cash Flow | -3,155 | -7,972 | -9,322 | -3,057 | -3,832 | -3,921 | Upgrade
|
Unlevered Free Cash Flow | -2,603 | -7,420 | -8,867 | -2,636 | -3,510 | -3,692 | Upgrade
|
Change in Net Working Capital | -1,186 | 3,469 | -1,257 | 918.14 | -273.87 | -765.31 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.